0001209191-23-030949.txt : 20230519 0001209191-23-030949.hdr.sgml : 20230519 20230519160518 ACCESSION NUMBER: 0001209191-23-030949 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230517 FILED AS OF DATE: 20230519 DATE AS OF CHANGE: 20230519 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bruhn Suzanne Louise CENTRAL INDEX KEY: 0001517790 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36257 FILM NUMBER: 23939995 MAIL ADDRESS: STREET 1: C/O AEGLEA BIOTHERAPEUTICS, INC. STREET 2: 901 S. MOPAC EXPRESSWAY, SUITE 250 CITY: AUSTIN STATE: TX ZIP: 78746 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Travere Therapeutics, Inc. CENTRAL INDEX KEY: 0001438533 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262383102 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3611 VALLEY CENTRE DR STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 888-969-7879 MAIL ADDRESS: STREET 1: 3611 VALLEY CENTRE DR STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Retrophin, Inc. DATE OF NAME CHANGE: 20130220 FORMER COMPANY: FORMER CONFORMED NAME: Desert Gateway, Inc. DATE OF NAME CHANGE: 20080625 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-05-17 0 0001438533 Travere Therapeutics, Inc. TVTX 0001517790 Bruhn Suzanne Louise C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DR., SUITE 300 SAN DIEGO CA 92130 1 0 0 0 0 Common Stock 2023-05-17 4 A 0 4500 0.00 A 15750 D Stock option (right to buy) 17.11 2023-05-17 4 A 0 13500 0.00 A 2024-05-17 2033-05-16 Common Stock 13500 13500 D Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. The equity award vests over a one year period. /s/ Elizabeth E. Reed, Attorney-in-Fact 2023-05-19